Welcome to our dedicated page for NYXOAH S A news (Ticker: NYXH), a resource for investors and traders seeking the latest updates and insights on NYXOAH S A stock.
Nyxoah SA reports medical-technology developments tied to the Genio system, its patient-centered, leadless and battery-free hypoglossal neurostimulation therapy for obstructive sleep apnea. Company news commonly covers financial and operating results, U.S. commercialization activity, regulatory status, manufacturing capacity, reimbursement references, investor conference participation, and the development and commercialization of OSA treatment alternatives.
Nyxoah also publishes regulated information for its Euronext Brussels and Nasdaq securities, including transparency notifications, shareholder-meeting materials, voting-right disclosures, and bond-related capital-structure notices.
Nyxoah (Euronext Brussels/Nasdaq: NYXH), a company developing breakthrough neuromodulation treatments for Obstructive Sleep Apnea (OSA), has scheduled the release of its fourth quarter and financial year 2024 results on March 13, 2025.
The company will host a conference call with management to discuss the financial results on the same day at 1:00pm CET / 8:00am ET. Investors can access the webcast through the company's Investor Relations page or participate in the Q&A session by registering for the earnings call at least 10 minutes before the start time.
Nyxoah (Euronext Brussels/Nasdaq: NYXH), a pioneer in Obstructive Sleep Apnea (OSA) treatment through neuromodulation, has announced its participation in the Oppenheimer 35th Annual Healthcare MedTech & Services Conference scheduled for March 17-20, 2025.
CEO Olivier Taelman will deliver a corporate presentation on Monday, March 17, 2025, at 8:40am ET. The presentation will be accessible via webcast in the Events section of Nyxoah's Investor Relations website. The company will also be available for one-on-one meetings with institutional investors during the conference.
Nyxoah (NYXH) has announced the commercial launch of its Genio system in the Middle East, marking a significant expansion of its neurostimulation therapy for Obstructive Sleep Apnea (OSA). The launch was highlighted by the first successful Genio implant at Saudi German Hospital in Dubai, UAE, performed by Dr. Ahmed Yassin Bahgat, Consultant Otolaryngologist.
This milestone represents the first-ever neurostimulation therapy for OSA in the Middle East region. The Genio system is designed as an alternative treatment for OSA patients who cannot tolerate CPAP therapy. The company emphasizes the system's innovative, clinically proven capabilities and its patient-centric approach.
Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) received a transparency notification from BlackRock, Inc. on January 16, 2025. The notification reveals that BlackRock and its controlled undertakings now hold 1,105,907 voting rights in Nyxoah, comprising 1,065,035 shares and 40,872 equivalent financial instruments. This represents 2.95% of total voting rights (37,427,265) as of January 14, 2025.
The change resulted in BlackRock crossing downward below the 3% threshold. The voting rights are distributed among various BlackRock entities, with BlackRock Advisors, holding the largest portion at 2.76%. The equivalent financial instruments include securities lent and contract differences, accounting for 0.10% of voting rights.
Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) received a transparency notification from BlackRock, Inc. on December 19, 2024. The notification reveals that BlackRock and its controlled undertakings now hold 1,124,630 voting rights in Nyxoah, comprising 1,122,658 shares and 1,972 equivalent financial instruments. This represents 3.00% of the total voting rights (37,427,265) as of December 17, 2024.
The holdings are distributed across various BlackRock entities, with BlackRock Advisors, holding the largest portion at 2.91% of voting rights. The notification was triggered by BlackRock's total holdings crossing above the 3% threshold.
Nyxoah has launched its Genio system commercially in England, with the first successful implants performed at University College London Hospitals (UCLH). The system, which treats Obstructive Sleep Apnea (OSA) through neuromodulation, is now covered under the NHS Specialised Services Devices Programme (SSDP). The first two patients received their implants from Mr. Ryan Chin Taw Cheong, Consultant ENT and Sleep Surgeon at UCLH. This launch marks a significant expansion of Nyxoah's innovative OSA treatment in the UK healthcare market.
Nyxoah SA (Euronext Brussels and Nasdaq: NYXH) has released an update on its voting rights and shares as required by Belgian law. The company reports a share capital of EUR 6,429,682.56 with 37,427,265 ordinary shares, each carrying one voting right. Additionally, there are 2,296,194 subscription rights to securities not yet issued, excluding 346,431 subscription rights that were issued but not yet granted.
Nyxoah (Euronext Brussels/Nasdaq: NYXH), a medical technology company focused on developing innovative Obstructive Sleep Apnea (OSA) treatments through neuromodulation, has announced its participation in the Piper Sandler 36th Annual Healthcare Conference. The company will deliver a presentation on Wednesday, December 4, 2024, at 2:00pm ET.
Interested parties can access a live audio webcast of the presentation through the investor relations section of Nyxoah's website at investors.nyxoah.com.
Nyxoah SA announces a special shareholders' meeting scheduled for December 19, 2024, at 3:00 p.m. CET at the company's headquarters. The meeting will address the approval of clauses in the EIB Agreements, including a loan facility and synthetic warrant agreement with the European Investment Bank. Key points include Change-of-Control Event provisions and voting procedures.
Shareholders can participate in person or via video conference, with voting available through mail or proxy before December 13, 2024. Registration date is set for December 5, 2024. The meeting requires no specific quorum, and decisions will be adopted by simple majority vote. Each share entitles one vote.
Nyxoah SA announced receiving a transparency notification from ResMed Inc. regarding a passive threshold crossing. According to the notification dated November 5, 2024, ResMed Inc. now holds 1,727,864 voting rights, representing 4.62% of the total voting rights (37,389,015) as of October 9, 2024. This represents a decrease below the 5% threshold. ResMed Inc. is not a controlled entity and holds these voting rights directly without any indirect holdings.